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Predictive modeling targets 
thymidylate synthase ThyX in 
Mycobacterium tuberculosis
Kamel Djaout1, Vinayak Singh2, Yap Boum3,4, Victoria Katawera3, Hubert F. Becker1,5, 
Natassja G. Bush6, Stephen J. Hearnshaw6,¶, Jennifer E. Pritchard6,§, Pauline Bourbon7, 
Peter B. Madrid7, Anthony Maxwell6, Valerie Mizrahi2, Hannu Myllykallio1 & Sean Ekins8,9
There is an urgent need to identify new treatments for tuberculosis (TB), a major infectious disease 
caused by Mycobacterium tuberculosis (Mtb), which results in 1.5 million deaths each year. We 
have targeted two essential enzymes in this organism that are promising for antibacterial therapy 
and reported to be inhibited by naphthoquinones. ThyX is an essential thymidylate synthase 
that is mechanistically and structurally unrelated to the human enzyme. DNA gyrase is a DNA 
topoisomerase present in bacteria and plants but not animals. The current study set out to understand 
the structure-activity relationships of these targets in Mtb using a combination of cheminformatics 
and in vitro screening. Here, we report the identification of new Mtb ThyX inhibitors, 2-chloro-3-(4-
methanesulfonylpiperazin-1-yl)-1,4-dihydronaphthalene-1,4-dione) and idebenone, which show 
modest whole-cell activity and appear to act, at least in part, by targeting ThyX in Mtb.
Tuberculosis (TB) is a major infectious disease that knows no geographic boundary and accounts for 9 million 
new cases and approximately 1.5 million deaths each year1. TB and its etiological agent Mycobacterium tuberculo-
sis (Mtb) are the focus of intense efforts to develop new tools for the control and eventual elimination2 of this dev-
astating disease, which is associated increasingly with resistance to first- and second-line drugs3. The discovery of 
new TB drug candidates with novel mechanisms of action that can overcome resistance, shorten the duration of 
treatment, and be co-administered with antiretrovirals, is of fundamental importance in this regard4–6. Over the 
last decade, there has been considerable investment in TB drug discovery with particular emphasis on the use of 
high-throughput phenotypic screening of libraries of thousands to hundreds of thousands of molecules for “hit” 
identification5,7–9. Whole-cell approaches have the advantage of allowing the high-throughput screening (HTS) 
assay to be conducted under conditions that mimic host infection without knowledge of mechanism of action10. 
Importantly, all presently used antibiotics have been developed by this approach, including the recently approved 
drug, bedaquiline11. Moreover, the phenotypic screening format produces a wealth of data that can be used for 
computational machine learning12, which has the potential to improve the screening efficiency of additional com-
pounds13,14 and assist lead optimization15.
An alternative approach to hit identification is target-based, which relies on the availability of purified pro-
tein against which a HTS can be performed10 and/or knowledge of the target, such as the crystal structure, to 
guide structure-based drug design. Drawbacks of this approach include the difficulty in balancing target activity 
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with the physicochemical properties needed to enter whole cells and evade efflux. This approach also requires 
extensive validation of the target. A recent review summarized the results of target-based and phenotypic 
screens conducted at the Novartis Institute for Tropical Diseases. After failing with target-based screens, phe-
notypic screens led to the identification of 5 chemical series in 7 years. Of these, 3 series were terminated due to 
glycerol-dependent activity which is irrelevant in Mtb, lack of in vivo activity, or limited maximum exposure10. 
Target-based screening has also been reviewed to identify the key properties of promising targets such as essen-
tiality for growth, vulnerability, druggability, reduced propensity for resistance, and target localization as well as 
amenability to chemotherapy16.
For a known target, computational approaches such as docking the molecules (into the protein structure), 
quantitative structure-activity relationship (QSAR), pharmacophore or machine learning models can be devel-
oped to screen chemical libraries12. We have previously used 3D pharmacophore models, alone or in combination 
with Bayesian models to identify compounds with antitubercular whole-cell activity17,18, as a bridge between 
phenotypic screening and rational structure-based drug design.
The current study focuses on naphthoquinone (NQ) compounds which have widely reported biological activ-
ities including anti-cancer and anti-malarial activities. For instance, atovaquone (2-(trans-4-(P-chlorophenyl)
cyclohexyl)-3-hydroxy-1,4-naphthoquinone), a well-known 2-OH-1,4-NQ, targets the respiratory electron trans-
fer chain, and is clinically used in anti-pneumocystis, anti-toxoplasmosis and anti-malarial treatments. NQs also 
have anti-microbial activity against different bacterial pathogens, including Mtb19–25. Recently, we showed that 
NQ-based compounds inhibit the activities of PBCV-1 and Helicobacter pylori thymidylate synthase ThyX26,27 as 
well as Mtb DNA gyrase28. These observations led us to investigate inhibition of Mtb ThyX by NQs and develop 
pharmacophore models for these two essential enzymes that are both required for DNA replication29.
ThyX is an essential thymidylate synthase (TS) that is both mechanistically and structurally unrelated to the 
analogous human enzyme30,31. These enzymes catalyze the methylation of 2′ -deoxyuridine-5′ -monophosphate 
(dUMP) to synthesize 2′ -deoxythymidine-5′ -monophosphate (dTMP), an essential DNA precursor. In this reac-
tion, 5,10-methylenetetrahydrofolate (CH2H4folate) and nicotinamide adenine dinucleotide phosphate (NADPH) 
are used as carbon and hydride donors, respectively. In the case of Paramecium bursaria chlorella virus-1  
ThyX, structural data have revealed stacking of NQ against the flavin adenine dinucleotide (FAD) co-factor, par-
tially overlapping with the dUMP-binding pocket27. As dUMP acts in the ThyX reaction both as the activator 
and the substrate32, NQ binding at the ThyX active site results in potent inhibition of ThyX activity. Importantly, 
unlike human TS, ThyX produces tetrahydrofolate (H4folate) as a byproduct explaining why many thyX-carrying 
organisms do not require dihydrofolate reductase (FolA)33. Strikingly, although mycobacteria possess two distinct 
families of thymidylate synthases, the canonical ThyA as well as the non-canonical ThyX, only ThyX is essential 
in these organisms34. ThyX thus represents a promising target against Mtb34,35, with a crystal structure available 
[PDB:2AF636]. Several laboratories have developed dUMP analogs to target Mtb ThyX, although most of the hits 
to date are non-selective and also inhibit ThyA37,38. More recently, conditional depletion of ThyX was shown to 
result in modest hypersensitivity of Mtb to the thymidylate synthase inhibitor and anticancer drug, 5-fluorouracil 
(5-FU)39, suggesting that inhibition of ThyX through metabolic conversion of 5-FU to 5-FdUMP comprises one 
element of the complex mechanism of anti-tubercular action of this drug.
NQs have also been shown to be active against DNA gyrase28 and appear to bind at the N-terminal domain 
of GyrB26 at a novel site that is distinct from the ATPase active site and the well-established binding site for ami-
nocoumarin antibiotics40. This enzyme is a topoisomerase present in bacteria and plants but not animals, and is 
a validated target for antibacterials that include the fluoroquinolones, which are important second-line drugs for 
TB. It consists of two subunits, GyrA and GyrB, which form an A2B2 complex in the active enzyme. DNA gyrase 
catalyzes supercoiling of DNA in an ATP-dependent reaction; the ATPase site resides in the GyrB subunit41.
The observed overlap of NQs binding and inhibiting both ThyX and GyrB from Mtb motivated the current 
study to identify new inhibitors suggested using computational approaches.
Results
Identification of NQs as inhibitors of ThyX and gyrase. In this study, we utilized a combined com-
putational and experimental workflow (Fig. 1) to obtain new insight into Mtb ThyX and DNA gyrase inhibition, 
and identify new inhibitors in the case of ThyX. A starting point for the study was the identification of NQs as 
inhibitors of Mtb ThyX and DNA gyrase (Supplementary Table 1). The compounds 2EO4 and C8-C1, originally 
identified as the inhibitors of the PBCV-1 ThyX enzyme, were found to also inhibit Mtb ThyX, but were inactive 
against Mtb gyrase. Diospyrin inhibits only Mtb gyrase whereas other tested molecules showed comparable activ-
ity against both enzymes (Supplementary Table 1). These results revealed that selective or dual inhibition of these 
enzymes is feasible and prompted further computational analyses to identify additional inhibitors.
Substructure searching and common features pharmacophores used for virtual screening with 
ThyX. Using the experimental data described in Supplementary Table 1, we were able to build common fea-
tures pharmacophores for Mtb ThyX and gyrase that consisted of excluded volumes, two hydrogen bond accep-
tors and one hydrophobic feature (Fig. 2). The Mtb GyrB pharmacophore used 6 NQs (Fig. 2A) and resulted in 
the same features as for the Mtb ThyX pharmacophore (Fig. 2B), albeit in a different arrangement. Isodiospyrin 
which inhibits GyrB was predicted to have a poor fit score against Mtb ThyX, as shown in Fig. 2C. After similarity 
searching previously identified whole-cell active compounds in the CDD TBDB42,43, using the napthoquinone 
substructure we identified a Mtb ThyX inhibitor, ethyl 3-(4-methylphenyl)-1,4-dioxonaphtalene-2-carboxylate 
(molecule B6, Fig. 3A), with a Ki of 4.5 μ M (Fig. 3B). This molecule as well as others screened in this process were 
added into the models to update them. All 19 compounds that we selected for GyrB at this stage were inactive 
(Supplementary Table 2); however, our approach led to additional compounds that showed substantial activ-
ity against ThyX. For example, one pharmacophore with 18 molecules (N18 Pharmacophore, Supplementary 
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Table 3) was used to search the NIH clinical collection of over 700 compounds, and one quinone compound, 
idebenone (Fig. 4A), was selected for testing based on its fit to the model (Fig. 4B). This molecule was found to 
be an uncompetitive inhibitor of Mtb ThyX with respect to dUMP (Ki = 3.3 μ M, Fig. 5), suggesting that it binds 
preferentially to the ThyX-dUMP complex. It also has weak whole-cell activity against Mtb, (MIC90 = 125 μ M; 
Supplementary Table 4). This table also shows the whole-cell activity of several other compounds against repli-
cating Mtb, including B6, D4, D5, E1, E10, F1 and F2 which were identified by screening against the Mtb ThyX 
(Fig. 1). Interestingly, menadione inhibited growth of Mtb while some additional analogs were less active or had 
solubility issues (Supplementary Table 5).
Predicting new ThyX inhibitors using Bayesian machine learning models. In prior work, we 
have used Bayesian machine learning to build models of whole-cell screens of small molecule compounds active 
against Mtb14, which led to the identification of new active compounds13,14,44. After testing 94 molecules against 
Mtb ThyX at 100 μ M (the training set, Supplemental Table 6), we generated a Bayesian model using molecules 
with > 70% inhibition as actives. This resulted in a promising model with a ROC score of 0.78 after 5-fold cross 
validation, alongside sensitivity, specificity and concordance values greater than 0.90 (Supplementary Fig. 1A). 
The ‘good’ features were predominantly quinones and NQs (Supplementary Fig. 1B), while ‘bad’ features included 
amines and sulfonamides (Supplementary Fig. 1C). A model with similar statistics was generated in CDD models 
using FCFP6 descriptors alone, with a 3-fold cross validation ROC score of 0.80 (Supplementary Fig. 2).
Experimental testing of Bayesian model for NQ inhibitors of ThyX. The Bayesian model generated 
with Discovery Studio was used to predict activity of 14 compounds (007B-010K, Supplementary Table 7) which 
were not included in the training set. The closest distance calculation uses the calculated Euclidean distance 
between each molecule and those in the training set and suggests they are different (a zero distance corresponds 
to identical molecules). Two of these molecules were predicted as “inactive” (010-I and 010-C, Supplementary 
Table 7). However, six of the remaining 12 compounds (50%) were predicted as actives and exhibited over 70% 
inhibition (the selected cut-off) of Mtb ThyX activity in vitro at 100 μ M. These experimental results illustrate the 
robustness of the models.
Figure 1. Workflow for combined computational and experimental approaches. In silico modelling and 
scoring of compounds is boxed in green. Enzyme assays are boxed in pink. Whole cell activity measurements 
are boxed in blue.
www.nature.com/scientificreports/
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Whole-cell activity against Mtb. We next investigated whole-cell activity of the NQs against laboratory 
and clinical isolates of Mtb with different drug resistance profiles to standard anti-tuberculars (Supplementary 
Figure 2. Initial common feature pharmacophores for ThyX and GyrB. (A) Diospyrin mapped to the GyrB 
model, (B) C8-C1 mapped to ThyX model. (C) ThyX model was used to score isodiospyrin (the fit was poor 
0.004). Blue = hydrophobe, green = hydrogen bond acceptor, grey = excluded volume.
www.nature.com/scientificreports/
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Table 8) under replicating conditions. MIC90 values of the molecules in the test set (Supplementary Table 7) 
ranged from 20 to 200 μ M (Supplementary Table 9).
Additional compounds that either acted as MtbThyX inhibitors in vitro or were selected by the N18 phar-
macophore model were also evaluated to identify those with growth inhibitory activity against replicating Mtb 
H37Rv (Supplementary Table 4). Molecules with whole-cell activity were then tested against a conditional knock-
down mutant of Mtb H37Rv, thyX Tet-OFF, in which thyX is expressed under the control of a Tet-regulated pro-
moter39. In this target-based whole-cell assay, compounds with ThyX-selective activity in Mtb can be identified on 
the basis of whether ThyX depletion confers hypersensitivity to the compound39,45. As expected, the positive con-
trol, 5-FU, showed a progressive, ATc-dependent shift in MIC90 from 3.1 μ M in the absence of ATc to 0.3 μ M at an 
ATc concentration of 6.2 ng/ml. Among the other compounds tested in this assay, two showed ≥ 4-fold increase 
in potency upon ThyX depletion, namely, E1 (2-chloro-3-(4-methanesulfonylpiperazin-1-yl)-1,4-dihydronap
hthalene-1,4-dione)) and idebenone (Fig. 6). These compounds demonstrated the same activity against thyX 
Tet-OFF in the absence of ATc compared to the H37Rv control, with MIC90 values of 62.5 and 125 μ M, respec-
tively. Addition of ATc resulted in a progressive increase in susceptibility to E1, with the MIC90 value decreasing 
to 15.6 μ M at an ATc concentration of 6.2 ng/ml. ThyX depletion also sensitized Mtb to idebenone with the MIC90 
shifting ~5-fold, from 125 μ M to 22 μ M. However, for reasons that are unclear, idebenone displayed atypical 
behavior in this checkerboard assay compared to 5-FU39 and E1, showing ~90% growth inhibition over an unu-
sually large concentration range (62.5–7.8 μ M) when added to thyX Tet-OFF in the presence of ATc at 6.2 ng/ml 
(Fig. 6B). Of the other compounds tested, F2 showed a slight (~2-fold) MIC90 shift (62.5 to 31.2 μ M) in the pres-
ence of ATc at 6.2 ng/ml, whereas no shift in MIC90 was observed for B6, D4, D5, E10 and F1. Together, these 
results implicate ThyX as a potential target for E1 and idebenone in Mtb.
Discussion
We have used a combination of cheminformatics and experimental strategies (Fig. 1) to identify new inhibitors of 
Mtb ThyX. Many previous studies have shown that NQs possess activity against Mtb19–25,28 and other bacteria27. It 
has long been suggested that such quinones are reactive and generally non-specific46, yet these natural products 
are already in therapeutic use, demonstrating that selective toxicity can be attained47,48. Starting with a set of NQs 
active against Mtb ThyX and/or GyrB (Supplementary Table 1), and employing a common feature pharmacoph-
ore approach, we showed that while a small set of compounds had identical pharmacophore features in each 
model, their arrangement was unique (Fig. 2). As we updated these models we noted little apparent change in the 
Mtb ThyX model and retrieved several compounds of interest for testing. However, the Mtb GyrB pharmacophore 
Figure 3. Structure and dose response curve for B6 against ThyX. (A) Structure of ethyl 3-(4-methylphenyl)-
1,4-dioxonaphtalene-2-carboxylate (B6), a NQ identified by similarity searching in the CDD Public database of 
previously tested compounds against Mtb with known whole cell activity. (B) B6 dose response curves versus 
ThyX.
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was unable to retrieve any additional active molecules containing NQ or other features (Supplementary Table 2). 
One of the compounds identified as active against Mtb ThyX using a pharmacophore based on NQs was ide-
benone (Figs 4 and 5), which demonstrate that the models can also retrieve non-NQs as ThyX inhibitors. Unlike 
the competitive mode of inhibition of NQs against PBCV-1 ThyX, idebenone exhibited uncompetitive inhibition 
of Mtb ThyX with respect to dUMP binding suggesting that it binds to, in addition to the free enzyme, to the 
Mtb ThyX-dUMP complex27. Idebenone has recently completed a phase III clinical trial for Duchene Muscular 
Dystrophy49. It is a potent antioxidant50 and can donate electrons to complex III of the electron transport chain. 
This drug has also found utility in studies on mitochondrial diseases including Friedreich’s Ataxia51 and is 
approved in Europe for Leber’s Hereditary Optic Neuropathy52. It is therefore possible that idebenone, while 
exhibiting only weak activity on Mtb whole cells, could have potential for repurposing against additional diseases 
as well. We also tested menadione and analogs that had improved whole cell activity (Supplementary Table 5) 
compared to idebenone. Menadione was inactive against Mtb gyrase but 7-methyljuglone, an analogue of mena-
dione, was active against both Mtb ThyX and gyrase, indicating that modification of a single hydroxyl in methyl-
juglone to a methyl group in menadione, participates in dual inhibition of Mtb ThyX and gyrase (Supplementary 
Table 1).
As we collected and tested a relatively large number of molecules (N = 94) against Mtb ThyX, we were able 
to use a machine learning approach. To our knowledge this represents the first target-based machine learn-
ing approach towards the identification of enzyme inhibitors in Mtb. Clearly, quinone and NQ substructures 
were identified as important for activity and molecules with amines and sulfonamides were less desirable. 
These machine learning results could help us focus on compounds to test in the future. The Bayesian model has 
the added advantage of being able to quickly score compounds so could narrow down potential compounds 
for testing. We evaluated the Bayesian model with additional NQs (Supplementary Table 7). Our model pre-
dicted potent new Mtb ThyX inhibitors that had some whole-cell activity against Mtb, thus attesting to the util-
ity of our approach. In addition we have used a second software tool (CDD Models) which produces a similar 
leave-out-cross-validation ROC value, with the advantage that this Bayesian model can be shared openly with 
others so that they can benefit from these modeling efforts53.
In this study we had greater success identifying additional inhibitors of Mtb ThyX than GyrB. While there is 
some inhibition overlap revealed by the NQs, this could suggest that the chemical property/feature permissive-
ness of Mtb ThyX is greater than GyrB due to differences in the binding site interactions. Substructure searching 
Figure 4. Idebenone mapped to the ThyX N = 18 pharmacophore model. (A) idebenone 2D structure.  
(B) Pharmacophore showing van der Waals surface based on C8-C1, Blue = hydrophobe, green = hydrogen 
bond acceptor, grey = excluded volume.
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for compounds previously identified in whole-cell screens against Mtb identified a NQ (B6) with activity against 
Mtb ThyX (Fig. 3) and moderate antibacterial activity on Mtb (Supplementary Table 4). Idebenone, while not 
particularly active in whole Mtb cells may target ThyX as part of its mechanism of action in Mtb. Therefore, 
idebenone could be a starting point for structure-based design or by creating new derivatives using our previ-
ous Bayesian models based on whole cell activity data14. The progress of idebenone in clinical trials and as an 
approved drug suggests that it is likely very acceptable from the point of view of physicochemical properties, 
formulation and safety.
In future work, new compounds could be evaluated with our previously published Bayesian models for whole 
cell activity14 alongside the current Mtb ThyX Bayesian model in order to prioritize molecules for testing. This 
would enable the optimization of both target and whole cell activity in parallel. We propose that a combination 
of pharmacophore modeling, target-based whole-cell assay and resultant machine learning molecules using this 
data could result in the identification of novel scaffolds for pursuit.
Methods
Compounds. Tested compounds were purchased from ChemBridge, Vitas-M Laboratory Ltd., InterBioScreen 
or Sigma and were > 90% pure (see Supplementary Table 6 for more details).
ThyX assays. Mtb ThyX activity was measured using the tritium release assay, as previously described 
for Helicobacter pylori ThyX26. Reaction mixture included 10 mM MgCl2, 300 mM NaCl, 500 μ M FAD, bovine 
serum albumin (200 μ g/ml), 250 μ M CH2H4folate (Eprova, Merck), 1 mM NADPH, 100 μ M dUMP, [5H3]dUMP 
(Moravek Biochemicals, CA, USA) and 1 μ M Mtb ThyX in 50 mM HEPES pH 8. DMSO concentration was 
maintained constant at 1%. Reactions were initiated by addition of NADPH (1 mM) at 37 °C and were stopped 
after 7 mins. For idebenone, IC50 value decreased as a function of increasing dUMP concentration indicating 
an un-competitive mode of inhibition. Therefore, the formula IC50 = Ki * (1 + Km/[S]) + [E]/2 where Km is the 
Michaelis constant for dUMP, [S] is the dUMP concentration, and [E] is the enzyme concentration in the assay, 
was used to convert a measured IC50 value to the corresponding Ki.
Gyrase assays. Mtb gyrase supercoiling assays were carried out as described previously54.
Drug susceptibility testing against Mtb. A resazurin (Alamar Blue) assay was used to assess activity 
against strains of Mtb55. The antimicrobial susceptibility test was performed in a clear-bottomed, round well, 
96-well microtiter plate. Compounds were tested at 8 concentrations ranging between 40 and 0.31 μ g/mL with a 
Figure 5. Idebenone dose response against ThyX and effect of dUMP. (A) Idebenone dose response curves 
versus ThyX. (B) Effect of the dUMP concentration on the IC50 value of Idebenone.
www.nature.com/scientificreports/
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final DMSO concentration of 1.25% in each well. After a growth medium containing ~104 bacteria was added to 
each well, the different dilutions of compounds were added. Controls included wells containing concentrations of 
rifampin and isoniazid ranging from 0.00039 to 8.0 μ g/mL to control for assay performance; wells with bacteria, 
growth medium, and vehicle (1.25% DMSO); and sterility control wells with medium. Plates were incubated at 
37 °C for 6 d in an ambient incubator at which time 5 μ L of 1% resazurin dye was added to each well. After 2 days 
of incubation, visual inspection of color (pink, periwinkle or blue) was recorded for each well along with meas-
urements of fluorescence in a microtiter plate fluorimeter with excitation at 530 nm and emission at 590 nm. The 
lowest drug concentration that inhibited growth of ≥ 90% of Mtb bacilli in the broth was considered the MIC90 
value56. Rifampicin and isoniazid were used as positive controls and were consistently in the acceptable range. 
Values were converted from μ g/ml to μ M throughout the paper, for consistency.
Target-based whole-cell screening. The susceptibility of Mtb H37Rv and a conditional knockdown of 
ThyX in Mtb, thyX Tet-OFF, to a subset of test compounds was also determined by the broth microdilution 
method, as described previously39. Briefly, bacteria were grown in Middlebrook 7H9 broth (BD) supplemented 
with OADC (BD), 0.2% glycerol and 0.05% Tween-80 to mid-exponential phase. The culture was diluted and 
~105 CFU/ml was added to a 96-well microtiter plate containing 2-fold serial dilutions of drug which was then 
incubated at 37 °C. For the pairwise combination (anhydrotetracycline (ATc) vs. test compound) assay using the 
thyX Tet-OFF strain, a two-dimensional array of serial dilutions of ATc and the test compound was prepared in a 
96-well plate. Control wells consisting of bacteria only or medium only were treated with the same concentration 
of DMSO as used in drug-containing wells. At day 7, 10 μ l of Alamar Blue solution (Invitrogen) was added and 
plates were reincubated at 37 °C. After 24 h, fluorescence (excitation 544 nm; emission 590 nm) was measured in 
a FLUOstar OPTIMA plate reader (BMG LABTECH, Offenberg, Germany). Data were normalised to the mini-
mum and maximum inhibition controls to generate a dose response curve (% inhibition) from which the MIC90 
was determined.
Substructure searching. The CDD database (Collaborative Drug Discovery Inc. Burlingame, CA) has been 
described previously and applied for TB research14. The literature data on Mtb drug discovery has been curated 
and 26 Mtb specific datasets (including published data from high throughput screens performed by NIAID/
Southern Research Institute have been compiled in the CDD Public database) are hosted, representing over 
Figure 6. Depletion of ThyX in Mtb confers modest hypersensitivity to E1 and idebenone. The effect of 
ThyX depletion on the susceptibility to E1 and idebenone was assessed using the thyX Tet-OFF mutant in a 
checkerboard assay. The H37Rv strain was used as a control. Bacterial viability was assessed by the Alamar 
Blue assay, measuring fluorescence at 544/590 nm. The numbers in parentheses denote the concentration of 
anhydrotetracycline (ATc, ng/ml), which modulates the expression of thyX in thyX Tet-OFF39. Ninety percent 
growth inhibition (MIC90) is represented by the dashed horizontal line. The results shown are representative of 
one of the three biological replicates.
www.nature.com/scientificreports/
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350,000 compounds derived from patents, literature and HTS data, and we have termed this the CDD TB DB. 
The NQ substructure was used to query these NIAID/Southern Research Institute data. Molecules which showed 
previously published good whole-cell activity (MIC90) were selected for testing. The data generated in this study 
were collected and uploaded in the CDD private Vault (http://www.collaborativedrug.com/register) from sdf files 
and mapped to custom protocols.
Common features pharmacophores. A set of NQs (Supplemental Table 1) was used to build common 
features pharmacophores for Mtb ThyX and GyrB with Discovery Studio 4.1 (Biovia, San Diego, CA) from 3D 
conformations of the molecules generated with the CAESAR algorithm. This identified key features for each 
protein. The pharmacophores were then used to search various databases (for which up to 100 molecule confor-
mations with the FAST conformer generation method with the maximum energy threshold of 20 kcal/mol, were 
created) such as the NIH clinical drugs set containing over 700 molecules. The pharmacophore models were 
updated as additional data were generated.
Bayesian models. We have previously described the generation and validation of the Laplacian-corrected 
Bayesian classifier models for Mtb14 using Discovery Studio 3.5 (San Diego, CA). The models were all gener-
ated using the following molecular descriptors: molecular function class fingerprints of maximum diameter 6 
(FCFP_6), AlogP, molecular weight, number of rotatable bonds, number of rings, number of aromatic rings, 
number of hydrogen bond acceptors, number of hydrogen bond donors, and molecular fractional polar surface 
area which were all calculated from input sdf files. This approach was applied to the ThyX data generated in this 
study using the cut off of 70% inhibition at 100 μ M to define actives. The resulting models were also validated 
using leave-one-out cross-validation; 5-fold validation to generate the receiver operator curve area under the 
curve (ROC AUC); concordance; specificity, and selectivity, as described previously. In the current study, as well 
as using the datasets individually, we also combined the datasets. Bayesian models were also generated in the 
CDD Vault using CDD Models, as described previously53. The current implementation used the FCFP6 finger-
prints alone, and by default 3-fold cross-validation is performed. The model can also be exported from CDD 
Vault for use in other open source software and mobile apps53.
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